Morbidity and Oncological Outcome After Curative Treatment in Sinonasal Squamous Cell Carcinoma
Ear, Nose & Throat Journal · 2025-06 · 104 (6)
DOI: 10.1177/01455613221117787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ear, Nose & Throat Journal, online erschienen am 06.08.2022. Verfasst von Ralph Hohenberger und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Paranasal Sinus Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
Sinonasal squamous cell carcinomas are rare and aggressive tumors. Curative therapy includes surgery and radiotherapy, with high risk for local morbidity and impaired quality of life. The objective of this study was to analyze a large cohort of patients with sinonasal squamous cell carcinoma on treatment morbidity and oncological outcome.
Methods
Patients with sinonasal squamous cell carcinoma (n = 75) treated at a tertiary referral center between 2008 and 2019 were identified. In patients with curative treatment intent (n = 70), a chart review and analysis on patient and tumor characteristics, morbidity, and oncological outcome was performed.
Results
Mean follow-up was 59 months. Primary curative therapy was surgery alone (n = 18), surgery with radiation (n = 25), and primary (chemo)radiation (n = 27). Forty-two (60%) patients suffered from treatment-related morbidity; most frequent symptoms were dry nasal mucosa (20%), nasal obstruction (14.3%), and vision impairment or loss (11.5%). Patients with early disease had less morbidity (51.4 vs 71.1%; P = 0.09), a lower recurrence rate (27% vs. 48.5%; P = 0.08), and better overall survival (92.5% vs. 71.1%; P = 0.01).
Conclusion
Treatment-related morbidity is common after curative treatment of sinonasal squamous cell carcinomas. Early disease is beneficial in terms of occurrence and severity as multimodal treatment and recurrence can more likely be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
- Department of Otorhinolaryngology, Head and Neck Surgery, Heidelberg University Hospital, Heidelberg, Germany.
- Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
ORCID-Profile: Ralph Hohenberger
Zitieren
APA
Hohenberger, R., Beckmann, S., Kaecker, C., Elicin, O., Giger, R., Caversaccio, M., & Anschuetz, L. (2025). Morbidity and Oncological Outcome After Curative Treatment in Sinonasal Squamous Cell Carcinoma. Ear, Nose & Throat Journal, 104(6). https://doi.org/10.1177/01455613221117787
Vancouver
Hohenberger R, Beckmann S, Kaecker C, Elicin O, Giger R, Caversaccio M, et al. Morbidity and Oncological Outcome After Curative Treatment in Sinonasal Squamous Cell Carcinoma. Ear, Nose & Throat Journal. 2025;104(6). doi:10.1177/01455613221117787
BibTeX
@article{Hohenberger2025,
author = {Hohenberger, Ralph and Beckmann, Sven and Kaecker, Christoph and Elicin, Olgun and Giger, Roland and Caversaccio, Marco and Anschuetz, Lukas},
title = {Morbidity and Oncological Outcome After Curative Treatment in Sinonasal Squamous Cell Carcinoma},
journal = {Ear, Nose & Throat Journal},
year = {2025},
volume = {104},
number = {6},
doi = {10.1177/01455613221117787}
}
EUVIMED